|LETTER TO THE EDITOR
|Year : 2015 | Volume
| Issue : 2 | Page : 337-338
Trends in the placement of penile prostheses over the last 17 years in France
Priscilla Leon1, Thomas Seisen1, Pierre Mozer1, Sébastien Beley2, Morgan Rouprêt1
1 Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6; UPMC University Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France
2 Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, Paris, France
|Date of Submission||10-May-2014|
|Date of Decision||15-Jun-2014|
|Date of Acceptance||06-Jul-2014|
|Date of Web Publication||16-Sep-2014|
Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6; UPMC University Paris 06, GRC n°5, ONCOTYPE-URO, Paris
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Leon P, Seisen T, Mozer P, Beley S, Rouprêt M. Trends in the placement of penile prostheses over the last 17 years in France. Asian J Androl 2015;17:337-8
|How to cite this URL:|
Leon P, Seisen T, Mozer P, Beley S, Rouprêt M. Trends in the placement of penile prostheses over the last 17 years in France. Asian J Androl [serial online] 2015 [cited 2021 Jul 27];17:337-8. Available from: https://www.ajandrology.com/text.asp?2015/17/2/337/139260 - DOI: 10.4103/1008-682X.139260
Erectile dysfunction (ED) currently affects 152 million men worldwide and this number is likely to reach 322 million by 2025.  Penile prostheses (PP) placement remains a last-resort option in cases where organic ED has not been cured by previous medications, notably intracavernosal injection and oral phosphodiesterase type-5 inhibitor. 
France ended 2013 with a population of 66 million inhabitants. In our study, we obtained data through the French national code registry database programme de mιdicalisation des systθmes d'information and from the patient-information forms filled out by the surgeon at the time of the implant. For claim purposes, this system comprehensively records information concerning every surgical procedure that is performed in a private or public hospital in France. Data were extracted for all patients who had undergone a penile implantation between 1997 and 2013.
Overall, 6982 PP were inserted over the last 17 years in France. We found that 2821 PP were implanted in France between 1997 and 2005 (i.e. mean number of 352.6 PP per year), and 4161 PP between 2006 and 2013 (i.e. the mean number of 594.4 PP per year) ([Figure 1]). Although the number of PP placements has increased considerably over this period, PP appears to be still underutilized in France compared with the USA, where they are used to treat ~ 10% of impotent men.  In addition, in the future, even more men are likely to develop ED associated with diabetes or other comorbidities, such as metabolic syndrome.
|Figure 1: Trends in penile prosthesis implantation between 1997 and 2013 in France.|
Click here to view
Overall, we found that 1182 revisions (16.9%) and 2264 explanations (32.4%) of PP occurred over the 17 years period ([Table 1]). PP implantation can require later revisions or even removal due to complications (i.e. infections or mechanical issues). In the literature, the main complication was infection, which developed in 1.7%-6.6% of cases.  In the largest French previous series, of 282 PP, sepsis occurred in 2.2% of cases, 5.6% of cases had mechanical dysfunction, and 9.3% of cases were in the iterative poses.  Wilson et al.  estimated that only 60% of first PP implants would survive for >15 years without revision or extraction. PP is efficacious in most men and have a satisfaction rate of 81% compared with 51% with sildenafil and 40% with intracavernosal injections. ,,,,
|Table 1: Trends in the numbers of PP devices implanted, the need for revision, and the explanation procedures used in France since 1997 |
Click here to view
As yet, PP is only implanted, in France, in a limited number of tertiary referent centers. It would be of benefit if these centers communicated with general practitioners and the general population on this successful therapeutic approach. In the light of current data, PP may be underused in France because medical personnel and the general population have little information on this therapy.
Finally, PP is really an expensive procedure, and cost can become an issue in many countries since few patients have the ability to afford the price of the device. However, the cost is not an issue in France as the health care system refund patients who require a PP, notably those who have diabetes and prostate cancer. Indeed, public hospitals do buy prostheses. The possibility of PP placement may depend on factors-related to catchment areas, patient recruitment, management, and strong differences in health care systems from country to another in the western world. Thus, we have no data to make a direct comparison between countries, and it is difficult to know whether these considerations can be translated in other countries.
| Author Contributions|| |
PL and TS extracted national data. PL and PM wrote the manuscript. SB was involved in the critical revision of the manuscript. MR was a senior author and initiated the conception and the draft of this letter.
| Competing Interests|| |
The authors declare that they have no competing interests.
| References|| |
Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int
1999; 84: 50-6.
Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, et al.
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol
2010; 57: 804-14.
Carson CC. Diagnosis, treatment and prevention of penile prosthesis infection. Int J Impot Res
2003; 15 Suppl 5: S139-46.
Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, et al.
Chapter 1: the management of erectile dysfunction: an AUA update. J Urol
2005; 174: 230-9.
Menard J, Tremeaux JC, Faix A, Staerman F. Penile protheses multicentre practice evaluation, results after 282 procedures. Prog Urol
2007; 17: 229-34.
Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med
2007; 4: 1074-9.
Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int
2006; 97: 129-33.
Chung E, Solomon M, Deyoung L, Brock GB. Clinical outcomes and patient satisfaction rates among elderly male aged ≥ 75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction. World J Urol
2014; 32: 173-7.
|This article has been cited by|
||Global Trends in Prevalence, Treatments, and Costs of Penile Prosthesis for Erectile Dysfunction in Men
| ||Taylor P. Kohn,Saneal Rajanahally,Wayne J.G. Hellstrom,Tung-Chin Hsieh,Omer A. Raheem |
| ||European Urology Focus. 2021; |
|[Pubmed] | [DOI]|
||Prótesis penianas: descripción de una serie de implantes con y sin dilatación de cuerpos cavernosos
| ||Daniela Fleck-Lavergne,Marcelo Marconi,Alejandro Mercado-Campero,Juan Pablo Hidalgo,Fernando Marchant,Cristián Palma-Ceppi |
| ||Revista Internacional de Andrología. 2019; |
|[Pubmed] | [DOI]|